No Data
No Data
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Announces Target Price $41
Express News | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings
Leerink Partners Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Announces Target Price $50
Viridian Therapeutics: Promising Market Position With Superior Efficacy and Safety of Veligrotug in TED Treatment